The Finaves-backed developer of brain implant technology based on research from University of Manchester has secured series A funding.
Inbrain Neuroelectronics, a Spain-based brain implant technology developer spun out of Catalan Institute of Nanoscience and Nanotechnology and Catalan Institution for Research and Advanced Studies, has secured €14.4m ($17m) in series A funding.
Venture capital firms Asabys Partners and Alta Life Sciences co-led the round, which included CDTI Innvierte, a vehicle formed by the Spanish Ministry of Science and Innovation, as well as Vsquared Ventures, TruVenturo and Institut Català de Finances’s ICF Venture Tech II fund.
Founded in 2019, Inbrain is developing a medical device based on graphene technology that can analyse and modulate brain activity. Its neuroelectronic therapies are aimed at patients with brain-related health conditions such as epilepsy and Parkinson’s disease.
The company’s technology uses intellectual property developed in collaboration with National Graphene Institute of University of Manchester.
Inbrain closed an undisclosed amount of seed funding in a June 2020 round featuring IESE Business…
